Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Investigator-Initiated, Open-Label, Phase II Trial of Selinexor in Combination With Pacritinib in Patients With Myelofibrosis Who Are JAK Inhibitor-Naïve and Have Cytopenias (ILLUMINATE)

NCT07447817 is registered in ClinicalTrials.gov with John Mascarenhas as lead sponsor.

NCT NCT07447817
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07447817 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Investigator-Initiated, Open-Label, Phase II Trial of Selinexor in Combination With Pacritinib in Patients With Myelofibrosis Who Are JAK Inhibitor-Naïve and Have Cytopenias (ILLUMINATE)
Lead sponsor
John Mascarenhas
Phase
Phase 2
Overall status
Not yet recruiting
Start date
May 4, 2026
Completion date
May 24, 2030
Enrollment
26 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

myelofibrosis, post-essential thrombocythemia myelofibrosis, post-polycythemia vera myelofibrosis